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ABSTRACT
Introduction The COVID-19 pandemic has emerged 
worldwide. Although several medications have been 
approved for treating moderate- to- severe COVID-19, 
very few treatment strategy has been established for 
patients with mild COVID-19 who do not require oxygen 
administration. Clarithromycin is a macrolide antimicrobial 
agent that has been widely used for bacterial respiratory 
infectious diseases. Clarithromycin also acts an 
immunomodulating drug and suppresses cytokine storms 
in viral respiratory diseases, including influenza. In this 
study, we aim to evaluate the efficacy of clarithromycin in 
patients with mild COVID-19.
Methods and analysis This is an exploratory, multicentre, 
open- label, randomised controlled trial. This study was 
initiated in May 2021 and will end in July 2022. Patients 
with mild COVID-19 pneumonia who do not require 
oxygen administration will be enrolled and randomly 
assigned in a 1:1:1 ratio to group A (administration of 
clarithromycin 800 mg/day), group B (administration of 
clarithromycin 400 mg/day) or group C (standard treatment 
without clarithromycin). The planned number of enrolled 
patients is 60 (20 patients × three groups). The primary 
endpoint is the number of days required to improve the 
clinical symptoms as measured by the severity score. 
Secondary endpoints include days for recovery of the 
body temperature, proportion of patients with oxygen 
administration, inflammatory cytokines, viral load, serum 
immunoglobulins, peripheral blood lymphocytes, blood 
biomarkers and pneumonia infiltrations.
Ethics and dissemination The study protocol was 
approved by the Clinical Research Review Board of 
Nagasaki University in accordance with the Clinical Trials 
Act in Japan. The study will be conducted in accordance 
with the Declaration of Helsinki, the Clinical Trials Act 
and other current legal regulations in Japan. Written 
informed consent will be obtained from all the participants. 
The results of this study will be reported as journal 
publications.
Trial registration number jRCTs071210011.
INTRODUCTION
The COVID-19 pandemic is currently a major 
concern worldwide. In Japan, a cumulative 
of 932 361 PCR test- positive cases have been 
confirmed, and 15 190 deaths were reported 
by the Ministry of Health, Labour and Welfare 
in Japan as of 1 August 2021.1 Approximately 
5% of the patients with COVID-19 were hospi-
talised, 1.6% had severe symptoms requiring 
intensive care and 1.0% died in Japan.2 
Recently, dexamethasone and remdesivir 
have been used as standard treatments for 
patients with moderate- to- severe COVID-19 
who require respiratory support,3–5 and the 
monoclonal antibody therapy, such as casiriv-
imab/imdevimab antibody cocktail, have 
been demonstrated as effective for mild to 
moderate COVID-19.6–8 However, these treat-
ments require intravenous drip infusion, and 
no oral medical treatment has been estab-
lished for mild COVID-19, which accounts 
Strengths and limitations of this study
 ► This is the first randomised controlled trial to eval-
uate the efficacy of clarithromycin in COVID-19 
pneumonia, especially in patients with mild 
COVID-19 pneumonia who do not require oxygen 
administration.
 ► The results of this study could contribute to the de-
velopment of new treatment strategies for COVID-19 
pneumonia.
 ► The major limitations of this study are its exploratory 
nature and relatively small sample size.
 ► Another limitation is the open- label study design and 
generalisability since this study is conducted only in 
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for the majority (approximately 80%) of patients with 
COVID-19.
The mechanism of exacerbation in COVID-19 has 
been reported to correlate with dysregulation of the 
immune response, resulting in exaggerated inflamma-
tion to produce excessive cytokines (the so- called cyto-
kine storm).9 Indeed, infection with the SARS- CoV-2 
induces high expression of inflammatory cytokines, such 
as granulocyte macrophage colony- stimulating factor and 
interleukin-6 (IL-6), thereby accelerating the inflamma-
tion.10 Therefore, suppression of inflammatory cytokines 
is an important target for preventing the exacerbation 
of COVID-19. This is supported by the evidence that 
tocilizumab, an antihuman IL-6 receptor monoclonal 
antibody that inhibits IL-6 signalling, and dexametha-
sone, anti- inflammatory and immunosuppressing steroid, 
reduced risk of mortality and exacerbation that required 
ventilation.11–13
Clarithromycin is a macrolide antibiotic that has been 
widely used as a monotherapy for bacterial respiratory 
infectious diseases. Clarithromycin has also been used as 
a standard combination therapy with beta- lactam antibi-
otics for severe community- acquired pneumonia,14 owing 
to its ability to suppress inflammatory cytokines.15 16 
Viral respiratory diseases, such as influenza, are not an 
exception in the mechanism of exacerbation, and combi-
nation therapy with clarithromycin and antiviral agents 
demonstrated clinical efficacy in influenza A infec-
tion.17 18 Considering the use of macrolides for COVID-
19, evidence in the efficacy of azithromycin to COVID-19 
is controversial; some reported the beneficial effect of 
azithromycin on COVID-19,19 20 while others reported no 
benefit in patients with COVID-19.21–23 Clarithromycin 
may have several advantages over azithromycin. First, clar-
ithromycin is well tolerated, with even lower frequency of 
adverse events (AEs)/side effects compared with azithro-
mycin.24 25 Second, dose of clarithromycin can be adjusted 
based on patients’ age, weight and symptoms by using 
a tablet of 200 mg in Japan. Third, clarithromycin and 
azithromycin affect differently to suppress immune cells 
and inflammatory cytokine production,26 27 and to inhibit 
NF-κB activation.28 Together with these, clarithromycin is 
a good candidate for alleviating symptoms and preventing 
the exacerbation of COVID-19 by suppressing inflamma-
tory cytokines and could be safely used in patients with 
COVID-19. This trial is planned to estimate the efficacy 
of clarithromycin in patients with mild COVID-19 pneu-
monia who do not require oxygen administration.
METHODS AND ANALYSIS
Study design and setting
‘The CAM (Clarithromycin) Effectivity for COVID-19 
pneumonia that does not require oxygen administration; 
multicenter, randomized- controlled, open- label, 3- armed 
parallel group comparison, exploratory trial’ (CAME 
COVID study) was initiated in May 2021, following the 
approval by the Clinical Research Review Board in Naga-
saki University in March 2021 and the registration/publi-
cation at the Japan Registry of Clinical Trials (jRCT) 
(registration number: jRCTs071210011) in April 2021. 
This study is scheduled to culminate in July 2022. Patients 
have been enrolled since May 2021, and enrolment will 
culminate in February 2022. This study will be conducted 
in 10 medical institutions in Japan (Nagasaki University 
Hospital, Nagasaki Harbor Medical Center, Sasebo City 
General Hospital, Japan Community Health Care Orga-
nization JCHO Isahaya General Hospital, Japanese Red 
Cross Nagasaki Genbaku Hospital, Hospital of the Univer-
sity of Occupational and Environmental Health, Japan, 
Wakamatsu Hospital of the University of Occupational 
and Environmental Health, Japan, Kitakyushu City Yahata 
Hospital, Fukuoka University Chikushi Hospital, and 
Saiseikai Nagasaki Hospital). As shown in figure 1, patients 
who are eligible for this study will be asked to participate 
in this study, and informed consent will be obtained 
prior to the registration/randomisation. After written 
consent is obtained from the eligible patients, they will be 
enrolled and randomised into group A (administration 
of clarithromycin 800 mg/day), group B (administration 
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of clarithromycin 400 mg/day) or group C (standard 
treatment without clarithromycin). The rationale for 
the doses of clarithromycin is as follows: clarithromycin- 
naproxen- oseltamivir combination therapy for Influenza 
A using 1000 mg/day of clarithromycin (500 mg twice 
daily) was tolerated and reduced mortality and length of 
hospital stay,17 and 400 mg/day and 800 mg/day of clari-
thromycin have been approved for bacterial respiratory 
infectious diseases and non- tuberculous mycobacterial 
infection, respectively, in Japan, and the safety of these 
doses of clarithromycin has been confirmed.
Sample size calculation
Since no prior clinical trial has evaluated the effect of clar-
ithromycin on COVID-19 pneumonia, no reference data 
are available for the statistical sample size calculation for 
this study. Therefore, this study is planned as an explor-
atory trial, and the target number of enrolled patients 
is defined as 60 (20 subjects×3 groups), based on the 
possible number of patients who could give their consent 
during the planned enrolment period in this study at the 
participating medical institutions.
Eligibility criteria
Patients with mild COVID-19 pneumonia who do not 
require oxygen administration will be included in this 
study. Mild COVID-19 is defined as SARS- CoV-2 positive 
and percutaneous arterial oxygen saturation (SpO2) of 
94% or higher in this study. This study will enrol patients 
with mild COVID-19 and with pneumonia. The detailed 
inclusion criteria are as follows: (1) patients in whom 
SARS- CoV-2 is detected by PCR tests or loop- mediated 
isothermal amplification method within 3 days before 
the informed consent, (2) patients with pneumonia by 
routine chest radiography or chest CT, (3) Japanese 
patients who are aged 20 years or older and (4) patients 
who give their written consent for participating in the 
study. The exclusion criteria are as follows: (1) patients 
who had symptoms of 8 days or longer, (2) patients who 
were treated with macrolide antimicrobial agents, (3) 
patients who were treated with steroids (except inhal-
ants) or immunosuppressive agents, (4) patients who 
are diagnosed with influenza viral infection, (5) patients 
whose SpO2 is 93% or less under room air condition, (6) 
patients with hepatic dysfunction (aspartate aminotrans-
ferase or alanine aminotransferase is more than five times 
the upper limit of normal in each medical institution or 
Child- Pugh B or C), (7) patients with renal dysfunction 
(creatinine is more than twice the upper limit of normal 
in each medical institution, and estimated glomerular 
filtration rate is less than 30 mL/min/1.73 m2), (8) 
patients whose peripheral blood neutrophils are less than 
1000 /µL, (9) patients who have a history of hypersen-
sitivity to macrolide antimicrobial agents, (10) patients 
who are pregnant or breast feeding, (11) patients who 
have a history of vaccination against COVID-19 and (12) 
patients with other conditions that the investigator thinks 
may render them inappropriate to participate in the 
study.
Recruitment and consent
The informed consent document (see online supple-
mental file 1) would be provided to the candidates who 
meet all of the inclusion criteria and who do not forsake 
any of the exclusion criteria to provide a comprehen-
sive explanation of this study. Written consent will be 
obtained. After obtaining consent, the participants will 
be enrolled in this study.
Random allocation
After obtaining informed consent, eligible patients are 
randomly assigned in a 1:1:1 ratio to group A (administra-
tion of clarithromycin 800 mg/day), group B (administra-
tion of clarithromycin 400 mg/day) or group C (standard 
treatment without clarithromycin). The randomisation 
sequence is generated using a computer- based dynamic 
allocation method with a minimisation procedure to 
balance the allocation factors (age ≥20 years and less than 
40 years, ≥40 years and less than 60 years or ≥60 years) 
and sex.
Study intervention and observation
All enrolled patients in this study will be hospitalised, 
since the Infectious Diseases Control Law in Japan desig-
nated COVID-19 as category II infectious diseases, which 
warrants the isolation of the patients, and the COVID-19 
infectious disease treatment guidelines by the Ministry 
of Health, Labour and Welfare in Japan29 warrant hospi-
talisation of the patients of COVID-19 with pneumonia. 
The enrolled patients will be subsequently observed for 
7 days30 for a comprehensive follow- up during the inter-
vention. Patients assigned to group A will commence 
with 400 mg of clarithromycin orally twice daily (after 
breakfast and supper) following hospitalisation. Patients 
assigned to group B will commence with 200 mg of clari-
thromycin orally twice daily (after breakfast and supper) 
following hospitalisation. Patients assigned to group C will 
commence with the standard care for COVID-19 pneu-
monia in each medical institution without the adminis-
tration of clarithromycin following hospitalisation. Since 
this is an open- label trial, placebo is not used in the group 
C. In groups A and B, clarithromycin is administered 14 
times (twice daily for 7 days). If the administration starts 
on the morning of day 1 (the day of hospitalisation), clar-
ithromycin will be administered until the evening of day 
7. If the administration starts on the evening of day 1, 
clarithromycin will be administered until the morning of 
day 8. The study patients are observed on days 1, 2, 3, 
4, 5, 6, 7, 8 and 14. The day of hospitalisation is consid-
ered the day when observation starts (reference date). 
During the study intervention period (days 1 to 7 or 8), 
the patients are not allowed to use macrolide antimicro-
bial agents, immunosuppressive agents or anticancer 
agents. Following the completion of the study interven-
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day 8 (post- treatment observation period), all the study 
patients will receive standard care for COVID-19 pneu-
monia in each medical institution without the administra-
tion of clarithromycin.
Table 1 shows the schedule of assessments performed 
at each observation point, including the mandatory and 
optional assessments. Inspection of subjects’ characteris-
tics (height, weight, body mass index, onset of COVID-
19, detection date of SARS- CoV-2, date of hospitalisation, 
anamnesis and comorbidity), vital signs (body tempera-
ture, systolic blood pressure, diastolic blood pressure, 
pulse, percutaneous oxygen saturation and frequency of 
breath), haematology tests (red blood cell, haemoglobin, 
haematocrit, white cell count, neutrophil, lymphocyte, 
eosinophil, monocyte, basophil and platelet), general 
blood biochemical tests (total bilirubin, aspartate amino-
transferase, alanine aminotransferase, alkaline phospha-
tase, gamma- guanosine triphosphate, total cholesterol, 
total protein, albumin, blood urea nitrogen, creatinine- 
estimated glomerular filtration rate based on creati-
nine, lactate dehydrogenase, creatine phosphokinase, 
brain natriuretic peptide, troponin T, C reactive protein, 
procalcitonin, ferritin, Na, pH, haemoglobin A1c and 
glucose), blood coagulation tests (prothrombin time, 
activated partial thromboplastin time and d- dimer), chest 
radiography and CT, and inspection of medications of 
other pharmaceutical agents are conducted by general 
inspection and interview. The severity of COVID-19 pneu-
monia is measured by the severity classification according 
to the COVID-19 infectious disease treatment guidelines 
by the Ministry of Health, Labour and Welfare in Japan29 
(mild: SpO2 ≥96%, no respiratory symptoms or only with 
coughing without dyspnoea and without pneumonia find-
ings; moderate I: 93% < SpO2<96%, with dyspnoea and 
with pneumonia findings; moderate II: SpO2 ≤93% and 
oxygen administration required; and severe: admission 
to intensive care unit or ventilator required), pneumonia 
severity index31 and A- DROP defined in the guidelines for 
the management of community- acquired pneumonia in 
adults released from the Japanese Respiratory Society,32 
the quantity of oxygen administered are recorded daily 
during hospitalisation, PCR tests for SARS- CoV-2 are 
conducted using nasopharyngeal swabs, 11) nasal drip 
tests are conducted for interleukin (IL)1beta, IL-6, IL-8, 
IL-10, IL-17, tumour necrosis factor- alpha, interferon- 
gamma, beta- defensin, granulocyte- macrophage colony- 
stimulating factor and immunoglobulin A, special blood 
tests are conducted for cytokines, chemokines, IL-33, 
immunoglobulin M, immunoglobulin G, and immuno-
globulin A, medication adherence of the study agent, 
meal intake, and subjective symptoms measured by the 
severity score33 are daily answered on the study patients’ 
diary by the study patients themselves.
Outcomes
The primary endpoint of this study is the number of 
days required to improve clinical symptoms, measured 
by the severity score33 by 50% or more from baseline. 
Secondary endpoints are as follows: (1) days to recover 
the body temperature to below 37°C following registra-
tion, (2) change in inflammatory cytokines in serum 
and nasal discharge from baseline, (3) proportion of 
patients in whom all the clinical symptoms measured by 
the severity score completely disappeared, (4) proportion 
of patients in whom each clinical symptom measured by 
the severity score is improved by 50% or more from base-
line, (5) reduction rate of the SARS- CoV-2 from baseline, 
(6) change in serum immunoglobulin G, immunoglob-
ulin M and immunoglobulin A antibodies from baseline, 
(7) recovery rate of peripheral blood lymphocytes, (8) 
proportion of patients with oxygen administration, (9) 
change in other general blood biomarkers and vital signs 
from baseline and (10) change in pneumonia image by 
chest radiography or chest CT. The severity score33 is 
measured by enquiring the effect of seven pneumonia- 
related symptoms (cough, shortness of breath, fatigue, 
headaches, anosmia, dysgeusia and general unwellness) 
on the patients’ daily life on a 4- point Likert scale (0=not 
affected, 1=little affected, 2=affected and 3=severely 
affected), and the number of days required to decrease 
the total score of the five symptoms by 50% or more from 
baseline will be analysed for the primary endpoint. The 
questionnaire for the severity score is shown in the online 
supplemental table 1.
Data collection, data management and monitoring
A case report form is used for data collection. A central 
registration number is used to identify the participants 
for anonymisation. Data collection and management 
are carried out by third- party entities to avoid bias. Data 
management is performed by Soiken, Data Management 
Group (Data Center). To manage and ensure quality, the 
study is monitored by Soiken, Monitoring Group.
Safety evaluation
During this study, the investigators constantly monitor 
any AEs through regular medical checkups. All the 
related AEs, not only side effects to the study agents but 
also any abnormal clinical laboratory test values and any 
untoward medical occurrence, are reported and docu-
mented. If the AEs meet the following criteria, the events 
are referred to as serious adverse events (SAEs) based on 
the ICH E2A, ICH E2D and the ‘Ethical Guidelines for 
Medical and Health Research Involving Human Subjects’ 
in Japan34: (1) AEs that result in death, (2) AEs that are 
life- threatening, (3) AEs that require hospitalisation or 
prolongation of existing hospitalisation, (4) AEs that 
result in persistent or significant disability or incapability, 
(5) other AEs that are medically important or critical, (6) 
AEs that are equivalently severe to criteria (1) to (5) and 
(7) AEs that are congenital abnormality or birth defects. 
AEs are followed up until normalisation or recovery to 
a level not considered to be an AE. The first hospitalisa-
tion following the registration to day 8 and prolongation 
of the first hospitalisation after day 8 without worsening 
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as AEs/SAEs in this study, since this study enrolled 
patients of COVID-19 with pneumonia who should be 
treated by hospitalisation until the complete disappear-
ance of pneumonia- related symptoms, according to the 
COVID-19 infectious disease treatment guidelines by the 
Ministry of Health, Labour and Welfare in Japan.29
Statistical analysis
All the tests will be two sided, and a p value of <0.05 will 
be considered statistically significant. A statistical anal-
ysis plan will be developed prior to the database lock. All 
the statistical analyses will be conducted by independent 
biostatisticians.
Three analysis sets are defined in this study; the full 
analysis set (FAS) included all the patients who are regis-
tered in this study and assigned to one of the intervention 
groups. However, patients with a severe protocol viola-
tion, such as registration without consent or registration 
out of the enrolment period, will be excluded from the 
FAS. The per- protocol set (PPS) excludes patients with a 
protocol violation from the FAS, such as violation of eligi-
bility criteria, use of prohibited or restricted concomitant 
drugs, or poor adherence to the study agent (less than 
75% or more than 120%). The safety analysis set includes 
all the patients who are registered in this study and receive 
at least one dose of the study agent or control treatment.
Patient characteristics at baseline will be presented 
as frequencies and proportions for categorical data, 
and summary statistics (number of patients, mean, SD, 
95% CI for mean, minimum, the first quartile, median, 
the third quartile and maximum) for continuous data. 
Patient characteristics will then be compared using the 
χ2 test or Fisher’s exact test for categorical endpoints and 
analysis of variance or Kruskal- Wallis test for continuous 
variables.
The primary endpoint of this study is the number of 
days required to improve the clinical symptoms measured 
by the severity score33 by 50% or more from the baseline. 
The primary endpoint will be analysed using the FAS 
and PPS. The cumulative incidence curves for the days 
required to improve the clinical symptoms measured by 
the severity score will be drawn, and a log- rank test with 
a closed testing procedure will be conducted for compar-
ison among the three groups. In addition, HRs among 
the groups will be estimated using the Cox proportional 
hazard model, and a 95% CI will be calculated. The HR 
adjusted by allocation factors (age and sex) as covariates 
will also be estimated.
For the secondary endpoints, summary statistics (number 
of patients, mean, SD, 95% CI for mean, minimum, the 
first quartile, median, the third quartile and maximum) 
for measurements, changes from baseline and per cent 
changes from baseline will be calculated for continuous 
data. Frequencies and proportions will be calculated for 
the categorical data. Two- sample t- test or Wilcoxon rank 
sum test for intergroup comparisons of the continuous 
data, one- sample t- test or Wilcoxon signed- rank test for 
intragroup comparisons of the continuous data and the 
χ2 test or Fisher’s exact test for intergroup comparisons 
of the categorical data will be performed. Multiplicity will 
not be adjusted for the secondary endpoints.
For the safety endpoints, summary statistics for the 
frequency of AEs will be calculated, and Fisher’s exact 
tests will be performed for intergroup comparisons. 
Multiplicity will not be adjusted for the safety endpoints.
Patient and public involvement
The patients and the public are not involved in the study, 
including planning, execution, analysis and evaluation.
Ethics and dissemination
This study and its protocol were approved by the Clinical 
Research Review Board of Nagasaki University (approval 
no. CRB20-027) in accordance with the Clinical Trials 
Act of Japan. The study will be conducted in accordance 
with the Declaration of Helsinki, the Clinical Trials Act 
and other current legal regulations in Japan. Written 
informed consent will be obtained from all participants 
after a full explanation of the study. The results of this 
study will be disseminated at medical conferences and 
through journal publications.
DISCUSSION
This is the first randomised controlled trial to evaluate 
the efficacy of clarithromycin against COVID-19 pneu-
monia. Although several in vitro or bioinformatics 
analyses have reported the positive effect of macrolide 
antimicrobial agents on coronaviruses,35 evidence in the 
efficacy of azithromycin to COVID-19 is still controver-
sial,19 20 and no clear clinical evidence has confirmed the 
efficacy of clarithromycin on coronaviruses, especially 
SARS- CoV-2. Although recent studies demonstrated the 
usefulness of monoclonal antibody therapy for mild to 
moderate COVID-19,6–8 no treatment strategy has yet 
been established to prevent exacerbation in patients with 
mild COVID-19 who do not require oxygen administra-
tion. In addition, since the monoclonal antibodies need 
to be administered to the patients by drip infusion, oral 
drug treatment could have an advantage, especially for 
persons receiving treatment or waiting for treatment at 
home or non- medical accommodation facilities. Develop-
ment of a proper treatment strategy for patients with mild 
COVID-19 is important, considering the medical aspects 
and in social and economic aspects, such as, for example, 
to reduce the hospital bed occupancy by patients with 
COVID-19 exacerbation or to suppress the treatment costs 
for patients with severe COVID-19. Clarithromycin may 
also contribute to the prevention of secondary infections 
owing to its antimicrobial/antiviral effects. Therefore, 
this study aims to evaluate the efficacy of clarithromycin 
in patients with mild COVID-19 pneumonia who do not 
require oxygen administration. The results of this study 
could contribute to the development of new treatment 
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Our study has several limitations. First, it is exploratory 
in nature. Owing to the lack of previous clinical evidence 
that evaluated the effect of clarithromycin on COVID-19 
pneumonia, the target number of enrolled patients is 
defined based on the feasible number of patients who can 
give their consent during the planned enrolment period 
in this study at the participating medical institutions. 
Second, the target sample size is relatively small. Third, 
this is an open- label trial. Thus, bias for the patients and 
investigators/physicians cannot be completely avoided. 
Fourth, this study is conducted only in medical institu-
tions in Japan and enrols only Japanese patients. These 
constraints could limit the generalisability of this study. 
Further international clinical trials on a larger scale are 
required in the future.
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